Cargando…
Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19
The novel human coronavirus-2 (HCoV-2), called SARS-CoV-2, is the causative agent of Coronavirus Induced Disease (COVID-19) and has spread causing a global pandemic. Currently, there is no vaccine to prevent infection nor any approved drug for the treatment. The development of a new drug is time-con...
Autores principales: | Husain, Amjad, Byrareddy, Siddappa N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536130/ https://www.ncbi.nlm.nih.gov/pubmed/33031791 http://dx.doi.org/10.1016/j.cbi.2020.109282 |
Ejemplares similares
-
Drug Repurposing Approaches to Combating Viral Infections
por: Trivedi, Jay, et al.
Publicado: (2020) -
A Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19
por: Shrimp, Jonathan H., et al.
Publicado: (2022) -
Rifampicin and Letermovir as potential repurposed drug candidate for COVID-19 treatment: insights from an in-silico study
por: Pathak, Yamini, et al.
Publicado: (2021) -
Drug repurposing for COVID-19: Approaches, challenges and promising candidates
por: Ng, Yan Ling, et al.
Publicado: (2021) -
Systematic Down-Selection of Repurposed Drug Candidates for COVID-19
por: MacRaild, Christopher A., et al.
Publicado: (2022)